How can we use anthracylines in the management of newly diagnosed metastatic breast cancer patients overexpressing HER-2?

被引：1
|
作者：
Harputluoglu, H. [1 ]
Altundag, K. [1 ]
机构：
[1] Hacettepe Univ, Inst Oncol, Dept Med Oncol, Ankara, Turkey
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷 / 06期
关键词：
D O I：
10.1093/annonc/mdn152
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1203 / 1203
页数：1
相关论文
共 50 条
  • [1] EGFR activity in Her-2 overexpressing metastatic breast cancer: evidence for simultaneous phosphorylation of Her-2/neu and EGFR
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 132 - 132
  • [2] Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC)
    Giuliani, Rosa
    Durbecq, Virginie
    Di Leo, Angelo
    Paesmans, Marianne
    Larsimont, Denis
    Leroy, Jean-Yves
    Borms, Marleen
    Vindeuoghel, Anita
    Jerusalem, Guy
    D'Hondt, Veronique
    Dirix, Luc
    Canon, Jean-Luc
    Richard, Vincent
    Cocquyt, Veronique
    Majois, Francoise
    Reginster, Michel
    Demol, Jan
    Kains, Jean-Pierre
    Delree, Paul
    Keppens, Carine
    Sotiriou, Christos
    Piccart, Martine J.
    Cardoso, Fatima
    EUROPEAN JOURNAL OF CANCER, 2007, 43 (04) : 725 - 735
  • [3] Lapatinib in the treatment of HER-2 overexpressing breast cancer
    Vrdoljak, E.
    Boban, M.
    Ban, M.
    JOURNAL OF BUON, 2011, 16 (03): : 393 - 399
  • [4] Vinorelbine and trastuzumab enhance effector cell function in patients with HER-2/neu overexpressing metastatic breast cancer
    Schwartz, GN
    Kaufman, PA
    Tretter, CPG
    Arrick, BA
    Mulrooney, TJ
    Connelly, EM
    Mellinger, DL
    Fisher, JL
    Ernsloff, MS
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S128 - S128
  • [5] How Can We Optimize Treatment of HER2-Positive Metastatic Breast Cancer?
    Hamilton, Erika P.
    Blackwell, Kimberly L.
    ONCOLOGY-NEW YORK, 2013, 27 (03): : 180 - 182
  • [6] Is there a role of anthracycline use in the management of de novo HER-2 positive metastatic breast cancer?
    Altundag, Kadri
    JOURNAL OF BUON, 2020, 25 (03): : 1667 - 1667
  • [7] Lapatinib prevents metastatic colonization of EGFR and Her-2 overexpressing breast cancer cells in the brain
    Gril, Brunilde
    Palmieri, Diane
    Hua, Emily K.
    Vega-Valle, Eleazar
    Herring, Jeanne
    Feigenbaum, Lionel
    Liewehr, David J.
    Steinberg, Seth M.
    Rubin, Stephen D.
    Steeg, Patricia S.
    CLINICAL & EXPERIMENTAL METASTASIS, 2009, 26 (07) : 880 - 880
  • [8] How we treat patients with metastatic HER2-positive breast cancer
    Nader-Marta, G.
    Martins-Branco, D.
    de Azambuja, E.
    ESMO OPEN, 2022, 7 (01)
  • [9] Her-2/neu amplification in the metastatic breast carcinomas from patients with Her-2/neu overexpressing or nonexpressing primary carcinoma.
    Xu, RL
    Perle, A
    Inghirami, G
    Chan, W
    Delgado, Y
    Feiner, H
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2000, 114 (04) : 656 - 657
  • [10] Trastuzumab (T) plus vinorelbine (VNR) as first combination in Her-2 overexpressing patients with metastatic breast cancer.
    Glogowska, I
    Sienkiewicz-Kozlowska, R
    Bauer-Kosinska, B
    Jaczewska, S
    Pienkowski, T
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 235S - 235S
12345